Globus Medical, Inc. (NYSE:GMED) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Globus Medical, Inc. (NYSE:GMED) have earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $106.3636.

Several research analysts have recently issued reports on the stock. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Needham & Company LLC upped their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Barclays increased their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company dropped their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th.

Globus Medical Stock Up 0.3%

GMED stock opened at $85.10 on Wednesday. The company has a market capitalization of $11.55 billion, a P/E ratio of 19.79, a PEG ratio of 1.75 and a beta of 1.00. The company has a 50-day simple moving average of $87.27 and a 200 day simple moving average of $88.32. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities analysts anticipate that Globus Medical will post 4.74 EPS for the current year.

Institutional Investors Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Glenmede Trust Co. NA lifted its holdings in Globus Medical by 22.8% in the 1st quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock valued at $19,424,000 after acquiring an additional 41,801 shares during the last quarter. Summitry LLC grew its position in Globus Medical by 2.6% in the first quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after buying an additional 211 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Globus Medical in the first quarter worth approximately $1,895,000. Janus Henderson Group PLC increased its holdings in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after buying an additional 328,217 shares in the last quarter. Finally, Arkadios Wealth Advisors lifted its position in shares of Globus Medical by 10.6% during the 1st quarter. Arkadios Wealth Advisors now owns 3,255 shares of the medical device company’s stock valued at $280,000 after acquiring an additional 312 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.